

ECONOMIC IMPACT OF A PHARMACOTHERAPEUTIC MANAGEMENT PROGRAM FOR ONCOLOGICAL PATIENTS





Uribe I¹, Rendón A¹, Madrigal J¹, Restrepo AM¹, Herrera R¹, Abad JM², Estrada Acevedo JI¹

¹HelPharma Medellín-Colombia.

² SURA EPS, Medellín, Colombia.

The management of cancer patients on oral chemotherapy presents significant challenges, including medication errors and adherence issues, which can impact both clinical outcomes and healthcare costs. This study evaluates the economic benefits of a pharmacotherapeutic management program, focusing on improving treatment safety, effectiveness, and resource utilization through continuous follow-up of oncology patients.

Objective

To describe the economic results of clinical follow-up and pharmacotherapeutic management of oncology patients.

Method

Descriptive cross-sectional study in patients diagnosed with cancer undergoing treatment with oral chemotherapy, evaluated by a team of physicians and pharmacists during 2023.


Through continuous pharmacotherapeutic follow-up, medication errors and problems in pharmacological adherence were detected and intervened to guarantee the pertinence, adherence, safety, and effectiveness of the treatments, and the rational use of health resources.

A univariate analysis was performed using the statistical package R Core Team Version 4.2 (2022).


Results

9709 patients were evaluated, and 262 cases were detected to intervene in 239 patients (2.5%), with a mean age of 59 years (SD=17), 66% women.

The pharmacological inefficiencies identified and managed were:



The drugs associated were mainly:



These pharmaceutical interventions represented savings equivalent to COP 196,8736,803 (501,125.42 USD).

Conclusion

Clinical follow-up and pharmacotherapeutic management in oncology patients allow for obtaining satisfactory clinical results and a significant economic impact on the health system.

Conflict of interest: none.